Author(s)

Robert B. Raffa^1,2,3, Joseph V. Pergolizzi Jr.^1,4, Robert Taylor Jr.⁴

¹Neumentum Inc.，Palo Alto,CA,USA.
²College of Pharmacy, University of Arizona, Tucson, AZ, USA.
³Temple University School of Pharmacy, Philadelphia, PA, USA.
⁴NEMA Research Inc., Naples, FL, USA.

General anesthetics constitute some of the most important and widely-used therapeutic drugs in the pharmacotherapeutic armamentarium. They are routinely used effectively and with adequate precaution-safety throughout the world for a multitude of clinical applications, predominantly as adjunctive agents for surgical procedures. Nevertheless, they have potential adverse effects (such as a drop in blood pressure and the inhibition of steroid production), particularly in vulnerable populations such as the very young and the frail elderly. It would be desirable therefore to have alternative agents that are just as efficacious, but have a better safety profile in a broader spectrum of patients. Toward this end, an anesthetic based on a unique chemical core (viz., an N-arylpyrrole derivative) has been reported in preclinical models to produce anesthetic effects without hemodynamic suppression. This lead could pave the way for new general anesthetics that are safer and easier to use.

General Anesthetic, Intravenous, Drug Discovery, GABAA Receptor, Molecular Modeling

Raffa, R. , Pergolizzi Jr., J. and Taylor Jr., R. (2019) Designing General Anesthetics That Have a Better Safety Profile. Pharmacology & Pharmacy, 10, 407-415. doi: 10.4236/pp.2019.1010033.